Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/128821
Título: | COVID-19 in Adults With Congenital Heart Disease | Autores/as: | Broberg, CS Kovacs, AH Sadeghi, S Rosenbaum, MS Lewis, MJ Carazo, MR Rodriguez, FH Halpern, DG Feinberg, J Galilea, FA Baraona, F Cedars, AM Ko, JM Porayette, P Maldonado, J Sarubbi, B Fusco, F Frogoudaki, AA Nir, A Chaudhry, A John, AS Karbassi, A Hoskoppal, AK Frischhertz, BP Hendrickson, B Bouma, BJ Rodriguez-Monserrate, CP Broda, CR Tobler, D Gregg, D Martínez Quintana, Efrén Yeung, E Krieger, EV Ruperti-Repilado, FJ Giannakoulas, G Lui, GK Ephrem, G Singh, HS Almeneisi, HMK Bartlett, HL Lindsay, I Grewal, J Nicolarsen, J Araujo, JJ Cramer, JW Bouchardy, J Al Najashi, K Ryan, K Alshawabkeh, L Andrade, L Ladouceur, M Schwerzmann, M Greutmann, M Meras, P Ferrero, P Dehghani, P Tung, PP Garcia-Orta, R Tompkins, RO Gendi, SM Cohen, S Klewer, S Hascoet, S Mohammadzadeh, S Upadhyay, S Fisher, SD Cook, S Cotts, TB Aboulhosn, JA |
Clasificación UNESCO: | 32 Ciencias médicas 320505 Enfermedades infecciosas |
Palabras clave: | Adult congenital heart disease Coronavirus COVID-19 Hospitalization |
Fecha de publicación: | 2021 | Publicación seriada: | Journal of the American College of Cardiology | Resumen: | Background: Adults with congenital heart disease (CHD) have been considered potentially high risk for novel coronavirus disease-19 (COVID-19) mortality or other complications. Objectives: This study sought to define the impact of COVID-19 in adults with CHD and to identify risk factors associated with adverse outcomes. Methods: Adults (age 18 years or older) with CHD and with confirmed or clinically suspected COVID-19 were included from CHD centers worldwide. Data collection included anatomic diagnosis and subsequent interventions, comorbidities, medications, echocardiographic findings, presenting symptoms, course of illness, and outcomes. Predictors of death or severe infection were determined. Results: From 58 adult CHD centers, the study included 1,044 infected patients (age: 35.1 ± 13.0 years; range 18 to 86 years; 51% women), 87% of whom had laboratory-confirmed coronavirus infection. The cohort included 118 (11%) patients with single ventricle and/or Fontan physiology, 87 (8%) patients with cyanosis, and 73 (7%) patients with pulmonary hypertension. There were 24 COVID-related deaths (case/fatality: 2.3%; 95% confidence interval: 1.4% to 3.2%). Factors associated with death included male sex, diabetes, cyanosis, pulmonary hypertension, renal insufficiency, and previous hospital admission for heart failure. Worse physiological stage was associated with mortality (p = 0.001), whereas anatomic complexity or defect group were not. Conclusions: COVID-19 mortality in adults with CHD is commensurate with the general population. The most vulnerable patients are those with worse physiological stage, such as cyanosis and pulmonary hypertension, whereas anatomic complexity does not appear to predict infection severity. | URI: | http://hdl.handle.net/10553/128821 | ISSN: | 0735-1097 | DOI: | 10.1016/j.jacc.2021.02.023 | Fuente: | Journal of the American College of Cardiology [0735-1097], v. 77(13), p. 1644-1655 (abril 2021) |
Colección: | Artículos |
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.